Cleerly

🫀 Proud to support the Society of Cardiovascular Computed Tomography Clinical Trials & Registries Award—recognizing research using CCTA to detect atherosclerosis. If you're leading a study focused on improving patient outcomes through advanced imaging, we’d love to see you apply. Applications are open through April 30. Let’s advance the future of cardiac care together! ❤️ #HealthcareInnovation #YesCCT #CTFirst

Missed our late-breaking research at #ACC25? AI-QCT reveals a critical insight: coronary plaque features carry a higher relative risk of major adverse cardiovascular events in women than in men. A heartfelt thank you to Dr. Gudrun Feuchtner, Alexander van Rosendael, MD PhD, Ibrahim Danad and all the CONFIRM2 investigators. Your dedication is paving the way for a more precise, proactive and personalized future in cardiac care. 🚀❤️ 👉 Read the full study here: https://lnkd.in/gjukXfWW #ClinicalResearch #AIQCT #YesCCT #CTFirst #HealthTech #HealthcareInnovation

That’s a wrap on #ACC25! 🎉 What a year! CCTA + AI analysis is gaining momentum, and we're more excited than ever about the future of cardiac care. Some of our favorite moments: ✨ Educating the Chicago community on AI-powered cardiac care at the American College of Cardiology's Community Health Fair ✨ A packed meet-and-greet with Cleerly leadership ✨ Fueling attendees with heart-healthy snacks & meals (We know some of you came for the food and we respect that 😉) ✨ Presenting late-breaker results demonstrating AI-QCT's predictive power for women's cardiovascular risk Gudrun Feuchtner, Alexander van Rosendael, MD PhD, Ibrahim Danad ✨ Connecting with colleagues, friends & innovators A huge thank you to the American College of Cardiology for an unforgettable event and for bringing thought leaders together to push cardiology forward. Missed us at the conference? Let's connect: https://lnkd.in/gdfHByJw #YesCCT #CTFirst #AIQCT #DigitalHealth #HealthcareInnovation

Don't be fooled, heart disease isn't a lost cause. With the right insights, we can empower patients to take control of their heart health. 💪❤️ From early detection to personalized care, it’s time to rethink heart attack prevention. Cleerly's AI-powered CCTA image analysis provides healthcare professionals with the data and clarity needed to make confident, informed decisions for their patients. 🩺💡 👉 Learn more here: https://lnkd.in/gEGM7ApB #HeartDisease #AprilFools #HealthcareInnovation #YesCCT #HeartAttacks

Behind every high-quality CCTA scan is a commitment to catching heart disease early and saving lives. 💪❤️ Congratulations to Envision Imaging at Plano on earning the Cleerly Certified Award! Their focus on high-quality CCTA imaging supports healthcare professionals in evaluating heart health with confidence. We're proud to partner with a team committed to raising the standard of cardiac care and empowering patients with clearer insights. 👏 🫶 #YesCCT #CCTA #CardiacImaging #CTScan #CTFirst

🚨Big news in Women’s Heart Health! 🚨Late-breaking research presented at #ACC25 reveals that AI-QCT enhances the identification of women at high risk for major adverse cardiovascular events (MACE). Led by Dr. Gudrun Feuchtner, this study reveals that specific plaque features in women present a higher risk for MACE compared to men. The research not only highlights the urgent need for tailored preventive strategies but also supports the adoption of AI-QCT into clinical practice for unbiased risk estimation in both men and women. Read the full press release to discover how this groundbreaking study could transform cardiac care for women: https://lnkd.in/gqP9MUWX #YesCCT #AIQCT #WomensHealth #HealthcareInnovation

✅ Day 2 at #ACC25 in the books! Thank you to everyone who stopped by our Meet & Greet to connect with our leadership and learn how Cleerly is transforming cardiac care with AI-powered, non-invasive tools for diagnosing and managing coronary artery disease. Our CEO & Founder, Dr. James Min, MD, joined a 'Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs. In a Lounge & Learn session, our VP of Medical Affairs, Michelle Gearhart, spoke on 'Increasing Female Physician Leadership in Clinical Trials. We're proud to be part of these vital discussions. 👏❤️ But we’re not done yet! There’s still plenty of heart talk ahead. 💙 Come visit us at booth 16033. We’d love to chat about how we can work together to create a world without heart attacks. 🗓️ Full schedule here: https://lnkd.in/gtdjSHwr #ACC25 #YesCCT #CTFirst #HealthcareInnovation

No lunch plans? No problem! 🥗❤️ Stop by booth 16033 for a meet & greet + lunch buffet with our leadership team at #ACC25! Meet the physicians, clinical innovators, and pioneers helping shape the future of cardiac care. Connect with Founder & CEO James Min, MD, CMO James P Earls MD, FSCCT, CSO Udo Hoffmann MD MPH, and CCO Jim Hartman over great food and even better conversation. See you there! 👋 #YesCCT #DigitalHealth #HealthcareInnovation

🚀 #ACC25 is here, and so is Cleerly! 🚀 We're live at Booth 16033, ready to connect, showcase our latest clinical insights and give you a hands-on look at how our AI-powered technology is shaping the future of cardiac care. Live demos, expert discussions, and game-changing research—don’t miss out! 👉 Check out our full schedule & book a meeting here: https://lnkd.in/gtdjSHwr #DigitalHealth #HealthcareInnovation #YesCCT #CTFirst

We track risk factors for coronary artery disease (CAD), but how are we tracking the disease itself? 🔍🫀 Meet Cleerly COMPARE a revolutionary feature that empowers physicians to track CAD over time to help personalize treatment and optimize patient care. With COMPARE, healthcare professionals can: 🔍 Assess plaque stabilization or progression with AI-powered insights 🎯 Help guide treatment using analyses of two or more CCTAs 📈 Evaluate CAD progression over time for truly individualized care This isn't just about detection, it's about taking action. Learn more here: https://lnkd.in/g9QTMQSZ #HealthcareInnovation #CoronaryArteryDisease #DigitalHealth #YesCCT #CardiacCare